If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
559.00    3.00 (0.54%)
Bid:
556.50
Ask:
557.00
Spread: 0.50 (0.09%)
Market Cap: £2.47b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Response to media speculation

26 Apr 2021 07:00

RNS Number : 5087W
Tate & Lyle PLC
26 April 2021
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT QUALIFIED OR MAY HAVE QUALIFIED AS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018

 

For immediate release

25 April 2021

 

Tate & Lyle PLC ("Tate & Lyle")

Response to media speculation

Tate & Lyle notes recent media speculation and confirms that it is in the process of exploring the potential to separate its Food & Beverage Solutions and Primary Products businesses through a sale of a controlling stake in its Primary Products business to a new long-term financial partner.

Tate & Lyle continues to successfully execute its strategy and remains confident in the future growth prospects of the company. However, the Board believes that if a transaction of this nature was completed it would enable Tate & Lyle and the new business to focus their respective strategies and capital allocation priorities and create the opportunity for enhanced shareholder value.

Discussions with potential new partners in the Primary Products business are at an early stage and therefore there can be no certainty that a transaction will be concluded. 

A further announcement will be made as and when appropriate.

The person responsible for making this announcement on behalf of Tate & Lyle is Claire-Marie O'Grady, Company Secretary.

Tate & Lyle's Legal Entity Identifier is 2138008K14474WPKZ244.

For more information, please contact Tate & Lyle PLC:

Christopher Marsh, VP, Investor Relations

Mobile: +44 (0)7796 192 688

 

Nick Hasell (FTI Consulting), Media Relations

Mobile: +44 (0)7825 523 383

 

 

About Tate & Lyle

Tate & Lyle PLC is a leading global provider of food and beverage ingredients and solutions. Supported by our 160-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients every day.

Through our expertise in sweetening, mouthfeel and fibre fortification, our Food & Beverage Solutions business develops solutions which reduce sugar, calories and fat, add fibre, and provide texture and stability in categories including beverages, dairy, bakery, soups, sauces and dressings. Our Primary Products business produces nutritive sweeteners, industrial starches used in paper and packaging, acidulants and products used for animal nutrition.

We have around 4,200 employees working in more than 60 locations across 30 countries. Tate & Lyle's purpose is Improving Lives for Generations and through our purpose we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2020, Tate & Lyle sales totalled £2.9 billion. For more information, please visit http://www.tateandlyle.com or follow Tate & Lyle on Twitter or LinkedIn.

Forward-looking statements

This announcement contains certain forward-looking statements with respect to the financial condition, results, operations and businesses of Tate & Lyle PLC. These statements and forecasts involve risk and uncertainty because they relate to events and depend upon circumstances that will occur in the future. There are a number of factors that could cause actual results or developments to differ materially from those expressed or implied by these forward-looking statements and forecasts.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RSPFLFESSLIEFIL
Date   Source Headline
2nd Sep 20258:00 amRNSTotal Voting Rights
11th Aug 20251:00 pmRNSDirector/PDMR Shareholding
5th Aug 20257:00 amRNSDirector/PDMR Shareholding
1st Aug 202511:00 amRNSTotal Voting Rights
24th Jul 20252:30 pmRNSResult of Annual General Meeting 2025
15th Jul 20251:00 pmRNSDirector/PDMR Shareholding
1st Jul 20253:30 pmRNSBlock listing Interim Review
1st Jul 20257:00 amRNSTate & Lyle Capital Markets Event
13th Jun 20253:00 pmRNSHolding(s) in Company
11th Jun 20254:30 pmRNSDirector/PDMR Shareholding
5th Jun 20252:30 pmRNSAnnual Financial Report and Notice of Meeting 2025
5th Jun 20252:00 pmRNSDirector/PDMR Shareholding
2nd Jun 202512:30 pmRNSTotal Voting Rights
28th May 202512:00 pmRNSDirector/PDMR Shareholding
27th May 202512:00 pmRNSDirector/PDMR Shareholding
23rd May 202510:00 amRNSDirector/PDMR Shareholding
22nd May 20257:00 amRNSFinal Results
14th May 20259:00 amRNSHolding(s) in Company
1st May 20253:00 pmRNSHolding(s) in Company
29th Apr 20253:30 pmRNSHolding(s) in Company
28th Apr 20255:15 pmRNSHolding(s) in Company
24th Apr 202512:00 pmRNSHolding(s) in Company
15th Apr 20257:00 amRNSIntegration update and pre-close statement
27th Mar 20257:00 amRNSDirectorate Change
14th Mar 202510:05 amRNSDirectorate declaration
11th Mar 20253:00 pmRNSHolding(s) in Company
5th Mar 202511:30 amRNSDirector/PDMR Shareholding
28th Feb 20254:30 pmRNSHolding(s) in Company
28th Feb 202510:15 amRNSDirector/PDMR Shareholding
27th Feb 20257:00 amRNSAdditional Listing
20th Feb 20251:42 pmRNSDirector/PDMR Shareholding
13th Feb 20257:00 amRNSTrading Statement
4th Feb 20257:05 amRNSDirector Declaration
3rd Feb 20253:30 pmRNSTotal Voting Rights
23rd Jan 20255:30 pmRNSIssue of Debt
9th Jan 20255:54 pmRNSCompletion of Share Buyback Programme
9th Jan 20255:45 pmRNSTransaction in Own Shares
8th Jan 20255:17 pmRNSTransaction in Own Shares
8th Jan 20252:02 pmRNSDirector/PDMR Shareholding
7th Jan 20255:31 pmRNSTransaction in Own Shares
6th Jan 20256:10 pmRNSTransaction in Own Shares
6th Jan 20252:00 pmRNSDirectorate Change
3rd Jan 20255:28 pmRNSTransaction in Own Shares
2nd Jan 20255:20 pmRNSTransaction in Own Shares
2nd Jan 20252:10 pmRNSBlock listing Interim Review
2nd Jan 20252:00 pmRNSTotal Voting Rights
30th Dec 20245:36 pmRNSTransaction in Own Shares
27th Dec 20245:15 pmRNSTransaction in Own Shares
23rd Dec 20245:26 pmRNSTransaction in Own Shares
20th Dec 20245:31 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.